<DOC>
	<DOC>NCT00606541</DOC>
	<brief_summary>Purpose of Study: To examine 1) the short and long-term effectiveness and tolerability of quetiapine (extended release) XR for the treatment of social anxiety disorder (SAD); and 2) continuation effects of quetiapine XR in preventing SAD relapse.</brief_summary>
	<brief_title>An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Adults 1865 years of age A primary diagnosis of SAD,using Diagnostic Standard Manual IV(DSMIV) criteria Minimum CGI severity score of 4 and minimum Brief Social Phobia Scale (BSPS) score of 20 at baseline Written informed consent A negative serum pregnancy test for women of childbearing potential. Current DSMIV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, mental retardation or other pervasive developmental disorder, or cognitive disorder due to a general medical condition Any current primary anxiety disorder other than SAD or current primary depression History of substance abuse or dependence within the last 6 months Suicide risk or serious suicide attempt within the last year Clinically significant medical condition or laboratory abnormality Women of childbearing potential who are unwilling to practice an acceptable method of contraception Subjects needing concurrent use of psychotropic medications History of hypersensitivity to quetiapine History of cataracts.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>Quetiapine XR</keyword>
	<keyword>Prevention</keyword>
	<keyword>tolerability</keyword>
</DOC>